Clinical Trial: A Post Authorization Registry Study of Participants Treated With LEQEMBI

U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07762092) titled 'A Post Authorization Registry Study of Participants Treated With LEQEMBI' on July 20.

Brief Summary: To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy [CAA]).

The seco...